CD70-specific T cells exhibit in vivo antitumor activity in an IP and systemic xenograft model of lymphoma. (A-B) Daudi cells (5 × 10⁵) expressing the eGFP-FFLuc gene were injected IP into SCID mice, and tumor growth was measured as increasing light signal (p/s/cm²/sr). On days 10, 11, and 17, mice were injected with 1 × 10⁷ CD70-specific or nontransduced T cells. Tumors treated with CD70-specific T cells regressed, whereas tumors treated with nontransduced T cells did not (P = .002) 7 days after treatment. Panel A shows images of representative animals. Panel B shows quantitative bioluminescence imaging. In panels C and D, Raji cells (2 × 10⁵) were injected intravenously into SCID mice. On days 4, 5, and 11, mice were injected with 1 × 10⁷ CD70-specific or nontransduced T cells. (C) Systemic tumors were enumerated using bioluminescence imaging. At weeks 3 and 4 after tumor cell injection, there was a significantly higher tumor burden in mice receiving nontransduced T cells than CD70-specific T cells (week 3, P = .012; week 4 [n = 12], P = .010). (D) Mice treated with CD70-specific T cells displayed a significant survival advantage over those receiving nontransduced T cells (P < .05).